Form for input on priorities for research and development for vaccines for important Transboundary
Animal Diseases for the National Veterinary Stockpile.
Please fill out one form for each disease.
Return the forms via email to iicab@iastate.edu by Friday, September 21, 2012.
Name (optional):___________________________________
Role in meeting:
_______Member of scientific advisory committee
_______Speaker
_______Participant
_______Academia
_______Industry
_______Federal Agency
_______Other:_________________
Recommendations for______________________________________:
Rift Valley Fever
HPAI
Exotic Newcastle disease
FMD
Nipah and Hendra
African Swine Fever
Classical Swine Fever Schmallenberg Virus
Q Fever
Heartwater
Ebola
Please indicate the level of importance for the following characteristics for an emergency use vaccine for
this disease:
H = High Priority
M = Medium priority
L = Low priority
NA = Not applicable for a vaccine for this disease
Leave blank = I don’t know






______Rapid onset of immunity
______Long duration of immunity
______Safe for manufacturing under BL2 conditions in a disease free country
______Broad protection for multiple strains or serotypes. Induction of heterosubtypic immunity
Induction of:
o ______Serum neutralizing antibody
o ______TH 1 cytokine response
o ______Cytotoxic T cells
o ______Mucosal IgA
o ______T cell mediated immunity at mucosal surface
Desirable characteristics for stockpiling for emergency use
o ______Ongoing manufacture and sale in endemic countries which enables indefinite
delivery/indefinite quantity (IDIQ) contracts for just in time delivery
o ______Stable when stored as bulk antigen
o ______Long self-life of finished vaccine
o ______Likelihood that it will protect against future strains/serotypes of pathogen













______Companion diagnostic test to detect infection in vaccinated animal (DIVA)
______Positive marker to detect vaccinated animals
______Capability to meet 9 CFR regulatory requirements for purity, potency, safety, and efficacy
______Capability to meet requirements for cost effective manufacturing and all proprietary
rights to vaccine antigen, vectors, and/or adjuvants
______Safe for use in food producing animals with no, or reasonably short, withdrawal time for
animal products for human consumption
______Not hazardous for humans accidentally exposed to the vaccine
______Suitable for mass vaccination strategies (eg. Oral delivery)
______Safety and efficacy in multiple species affected by the pathogen (list species)
______Vaccine capable of being delivered to wildlife (eg. In baits)
______Knowledge of level of herd immunity needed to stop transmission in a population
(Reproduction ratio)
______Thermostability to maintain efficacy in absence of a reliable cold chain
______Compatible with World Organization for Animal Health (OIE) requirements for safety and
efficacy of vaccines for international trade
______Other:
What are the best near term opportunities for developing a vaccine for the NVS?
What are the major deficiencies of current vaccines and vaccines under development?
Are there major research questions which need to be answered before vaccines (or improved vaccines)
can be developed for this disease? If so, what are they?
What technology shows the greatest promise for long term development of a next generation vaccine
for the NVS?
Other Comments: